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ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapies that
specifically target the CD19 antigen have emerged
as a highly effective treatment option in patients with
refractory B-cell hematological malignancies. Safety
and efficacy outcomes from the pivotal prospective
clinical trials of axicabtagene ciloleucel, tisagenlecleucel
and lisocabtagene maraleucel and the retrospective,
postmarketing, real-world analyses have confirmed high
response rates and durable remissions in patients who
had failed multiple lines of therapy and had no meaningful
treatment options. Although initially administered in the
inpatient setting, there has been a growing interest in
delivering CAR-T cell therapy in the outpatient setting;
however, this has not been adopted as standard clinical
practice for multiple reasons, including logistic and
reimbursement issues. CAR-T cell therapy requires a
multidisciplinary approach and coordination, particularly
if given in an outpatient setting. The ability to monitor
patients closely is necessary and proper protocols must
be established to respond to clinical changes to ensure
efficient, effective and rapid evaluation either in the clinic
or emergency department for management decisions
regarding fever, sepsis, cytokine release syndrome and
neurological events, specifically immune effector cell-
associated neurotoxicity syndrome. This review presents
the authors’ institutional experience with the preparation
and delivery of outpatient CD19-directed CAR-T cell
therapy.

INTRODUCTION
Chimeric antigen receptor (CAR) T-
cell
therapy involves the genetic engineering of
a patient’s own T cells to express CARs that
are engineered to target specific epitopes of
tumor-associated antigens expressed on the
target cell surface.1 The aim of current CAR-T
cell therapy is the redirection of cellular cytotoxicity to malignant cells. Immune effector
cell toxicities may vary between different
agents, such as tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
and most recently brexucabtagene autoleucel, based on variations in CAR structure
and signaling, disease entity treated and

manufacturing differences. These variations
may affect the time to emergence and severity
of complications and factor into adopting
inpatient versus outpatient CAR administration (box 1).2 3
Tisagenlecleucel is approved for patients
up to 25 years of age with B-cell precursor
acute lymphoblastic leukemia (B-ALL) that
is refractory or in second or later relapse.4
Tisagenlecleucel and axicabtagene ciloleucel are both approved for adult patients
with relapsed or refractory (r/r) large B-cell
lymphoma after two or more lines of systemic
therapy, including diffuse large B-
cell
lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma (HGBCL) and
transformed DLBCL (tDLBCL) arising from
follicular lymphoma (FL).4 5 Axicabtagene
ciloleucel is also approved for treatment of
patients with r/r primary mediastinal large
B-cell lymphoma (PMBCL).5 Lisocabtagene
maraleucel is a CAR-
T cell therapy tested
in patients with DLBCL and was recently
approved (February 5, 2021) by the US Food
and Drug Administration. Brexucabtagene
autoleucel is a recently approved CAR-
T
product for relapsed or refractory mantle cell
lymphoma (online supplemental table 1).
This review presents the authors’ institutional
approach to and experience with outpatient
administration of CD19-directed CAR-T cell
therapy in adult patients with r/r DLBCL.
Outpatient administration of CAR-
T cell
therapy in pediatric and young adult patients
with r/r B-ALL is also discussed.

CAR-T CELL THERAPY EFFICACY
Clinical trials in patients with r/r DLBCL
Clinical trials of CAR-T cell therapies have
demonstrated high response rates that are
durable in patients with r/r DLBCL (online
supplemental table 2). The pivotal ZUMA-1
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Preinfusion
►► Consider the patient’s predicted time to onset of CRS and NE (ie,

early vs late).
►► Evaluate the patient’s degree of socioeconomic support, includ-

ing the level of social/familial support, as assessed by social work
services.
►► Consider feasibility of an individual infusion room.
►► Confirm patient’s possession of the wallet card for instructions concerning potential complications.
►► Communicate with the manufacturing facility to ensure that manufacturing will be completed and the product will be shipped at the
appropriate time.
►► Instruct the patient to remain within a 1-hour transportation distance from the outpatient center for at least 4 weeks postinfusion.a
►► Complete COVID-19 testing prior to infusion.

Postinfusion
►► Monitor the patient at the certified healthcare facility frequently

during the first week for signs and symptoms of CRS and ICANS,
tumor lysis syndrome and cytopenias.
►► Continue prophylactic treatment with antibiotics and other supportive care.
►► Ensure communication with on-call oncology and emergency department teams concerning the patient’s treatment with CAR-T cell
therapy.
►► Consider hospital admission if:
–– The patient develops a fever (≥38°C).
–– Fever is present in a patient with a high predicted risk for progression to severe complications (eg, high baseline tumor burden).
►► For discharge after admission, consider timing of fever resolution
from CAR-T infusion, presence/absence of documented infections
and neutrophil recovery.
a
Patients considered ‘high risk’ due to tumor bulk >10 cm. Nastoupil,2
high lactate dehydrogenase3 and multiple preexisting medical comorbidities, for example, are commonly instructed to remain within a 30
min transportation distance; if possible, it is preferable for patients to
be housed in close proximity to the institution.
CAR-T, chimeric antigen receptor T-cell; CRS, cytokine relsease syndrome; ICANS, immune effector cell-
associated neurotoxicity syndrome; NE, neurological events.

trial (NCT02348216) is a phase 2, single-arm study of
axicabtagene ciloleucel in patients with DLBCL, transformed FL (tFL) or PMBCL.6 The pivotal JULIET trial
(NCT02445248) is a phase 2, single-arm study of tisagenlecleucel in patients with r/r DLBCL or tFL.3 Lastly, the
phase 1 TRANSCEND-
NHL-001 trial (NCT02631044)
enrolled patients with DLBCL, tFL, FL grade 3B,
HGBCL, mantle cell lymphoma, PMBCL or tDLBCL.7
Of note, in ZUMA-1 all patients had refractory disease
(according to SCHOLAR-1 criteria) and bridging chemotherapy was not permitted, whereas JULIET and TRANSCEND-NHL-001 included patients with r/r disease and
the option for bridging chemotherapy (used in 90% and
59% of patients, respectively).
2

Postmarketing experience of CAR-T cell therapy in patients
with r/r DLBCL
Several multicenter retrospective analyses have examined
patient and disease characteristics, clinical outcomes
and complications using postapproval data from the
Center for International Blood and Marrow Transplant
Research Cellular Therapy Registry, the US CAR-T Cell
Consortium, and institutions using commercially available CAR-T cell therapies. Demographics and baseline
disease characteristics for patients included in these
descriptive retrospective analyses of tisagenlecleucel and
axicabtagene ciloleucel show significant drift from the
restrictive eligiblity of the clinical trials.2 8–11Despite an
older, broader patient population with more comorbidities in the postapproval setting (>50% of patients would
not have qualified based on ZUMA-1 eligibility criteria12),
efficacy outcomes similar to those observed in clinical
trials for both CAR-T cell therapies were reported across
treatment settings (online supplemental tables 2–3).2 8 10
Clinical trial and postmarketing experience of CAR-T cell
therapy in patients with r/r B-ALL
Currently, tisagenlecleucel is the only CAR-T cell therapy
approved in pediatric and young adult patients with r/r
B-ALL. The ELIANA clinical trial is a phase 2, multicenter,
global study of tisagenlecleucel in children and young
adults with r/r B-ALL (NCT02435849).13 The real-world
data in a similar patient population confirms the efficacy findings from the ELIANA trial, and more favorable
safety findings compared with the ELIANA trial support
the benefit of CAR-T cell therapy in pediatric and young
adult patients with r/r B-
ALL (online supplemental
tables 2–3). Additionally, this experience may suggest that
lessons from the clinical trial, as well as enhanced manufacturing capability,14 may be translated into an improved
safety profile for tisagenlecleucel in pediatric and young
adult patients with r/r B-ALL.
CAR-T CELL THERAPY SAFETY
These groundbreaking effector cell-based therapies have
revealed novel toxicities not previously seen with other anticancer therapies, including potentially life-
threatening
events such as cytokine release syndrome (CRS) and
neurological events (NE), particularly immune effector
cell-
associated neurotoxicity syndrome (ICANS; online
supplemental tables 2–3). Considering the differences in
grading and management of CRS and NE,15–22 in addition
to new learnings that have changed practices over time, it
can be challenging to use the current reported trial data to
assess patient risk and suitability for outpatient CAR-T cell
therapy administration. The anticipated timing and probability of these complications may influence outpatient
treatment decisions and be a determining factor in the
inpatient versus outpatient treatment recommendation.
In addition, the authors are not aware of any published
randomized data demonstrating differential efficacy or
safety for tisagenlecleucel or lisocabtagene maraleucel
Myers GD, et al. J Immunother Cancer 2021;9:e002056. doi:10.1136/jitc-2020-002056
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OUTPATIENT PREPARATION AND INFUSION
Procedural considerations for the multidisciplinary team
that administers CAR-T cell therapy and manages patients
before, during and after CAR-T cell infusion apply to both
the inpatient and outpatient settings, including limitation
of precollection treatments that could induce subsequent
CAR-T cell dysfunction, addressing the timing of apheresis, disease status, clinical laboratory testing and the use
of bridging and lymphodepleting chemotherapy.4 5
For outpatient infusion of tisagenlecleucel, an individual infusion room, rather than an open-air infusion
chair, is preferred given the need for monitoring and
the potential for infusion reactions, similar to situations
for outpatient autologous transplantation. However,
the small volume and number of thawed cryopreserved
CAR-T cells make this a rare event. Similar monitoring is
Myers GD, et al. J Immunother Cancer 2021;9:e002056. doi:10.1136/jitc-2020-002056

needed for administration of lisocabtagene maraleucel,
but it is important to note that the independent CD4 and
CD8 components are administered by direct ‘slow’ intravenous push and with a defined constituent administration order of the CD4 and CD8 fractions.31

INPATIENT VERSUS OUTPATIENT INFUSION
With commercialization, there is continually expanding
interest in administering all CAR-T cell therapies in the
outpatient treatment setting based on a risk–benefit
assessment, greater predictability of clinical course,
patient preference, limiting resource utilization and
controlling reimbursement uncertainty. Although CAR-T
cell therapies can be administered safely in the outpatient setting, most patients still receive treatment in an
inpatient setting. The choice of outpatient administration of CAR-T cell therapy is influenced by several
factors. First, specific institutional training and safeguards must be implemented prior to outpatient administration, including education of the patient, physician
(including on-call physicians), the infusion center and
emergency department personnel. Second, covering
practice providers should be alerted that an outpatient
has been infused with CAR-T cell therapy and could experience complications requiring early intervention. Third,
better understanding of predictive risk factors for the
likelihood of CRS development can influence the decision of whether to pursue outpatient infusion. Variation
in reimbursement policies, including whether patients
have public or private insurance, has had drastic implications for institutions, payers and patients. Additionally,
adequate caregiver education and support is key for safe
outpatient administration. Finally, in response to the
COVID-19 pandemic, commercial CAR-
T cell therapy
has been administered in the inpatient setting to ensure
bed availability in case complications were encountered.
Despite the perceived hurdles associated with outpatient
administration of CAR-T cell therapy, growing real-world
experience, including the ability to modulate disease
burden and timing of CAR-T cell infusion, supports the
T cell therapy in the outpatient
safe delivery of CAR-
setting. In fact, the capability of patients to return to the
hospital for fever may influence the decision to infuse
and monitor in the inpatient setting to a greater extent
compared with these other factors.
Feasibility of outpatient administration
The feasibility of outpatient administration (including
infusion, patient monitoring and adverse event management) in the clinical trial setting has been shown in
patients in the JULIET and TRANSCEND (r/r DLBCL)
and ELIANA (r/r ALL) trials.32–34 In the JULIET trial,
27% of patients were infused in the outpatient setting.4
In the ELIANA trial, 24% of patients received their infusions in the outpatient setting.33 A total of 59 patients
(18%) were treated with lisocabtagene maraleucel in
the outpatient setting from three clinical trials with
3
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administered in the outpatient versus inpatient setting,
suggesting that clinical outcomes are not affected by the
inpatient versus outpatient treatment decision. However,
26% of patients received outpatient treatment in JULIET;
of those admitted, many were discharged after a limited
observation period. In contrast, a 7-day hospital stay was
mandated in ZUMA-1.6
The 4 CAR-T cell therapies differ in their cosignaling
molecule/activation domains: the CD28 activation
domain within axicabtagene ciloleucel and brexucabtagene autoleucel is believed to amplify early CAR-T cell
expansion postinfusion,23 and the 4-
1BB activation
domain within the tisagenlecleucel and lisocabtagene
maraleucel CARs is believed to confer slower expansion
and prolonged CAR-T cell persistence.24 Compared with
the CD28 activation domain containing axicabtagene
ciloleucel, the later onset of CRS observed in clinical trials
with the 4-1BB activation domain CARs tisagenlecleucel
and lisocabtagene maraleucel have facilitated adoption
of outpatient administration of these therapies (online
supplemental table 2).25 It is apparent that CRS and NE
management strategies used in the real-
world setting
have confirmed the benefit of increased and earlier
use of tocilizumab and corticosteroids for CRS and NE
compared with the standard algorithms used in clinical
trials, and these medications are now recommended in
recent management guidelines.16 19 26 Early clinical trials
of CAR-T cell therapies have used the Common Terminology Criteria for Adverse Events to define NE, which
include vague, overlapping, subjective terms that may
not be clinically relevant to management of CAR-T cell
therapy-induced NE. In comparison, ICANS defines the
adverse events resulting from T-cell effects on the central
nervous system (CNS), which can result from immune
therapies, including CAR-
T cell therapy. Management
strategies used in the real-world setting have also evolved
to better characterize ICANS.7 8 10 11 27–30 Overall, real-
world and clinical trial data suggest that earlier corticosteroid and tocilizumab use does not influence efficacy,
although they appear to mitigate CRS intensity.

Open access

Considerations for the outpatient administration decision
Patient-
specific factors must be assessed for inpatient
versus outpatient administration. In clinical practice
4

with tisagenlecleucel, physician preference for outpatient administration will depend on the available institutional resources (eg, training classes for the patient and
caregiver and support for a 24-hour consultation to evaluate CAR-T cell therapy-related toxicity), the feasibility
of the patient remaining within close proximity to the
center, and the level of caregiver support. The primary
considerations for determining individual patient suitability for outpatient administration are often the probability, severity, and the predicted time to onset (ie, early
vs late) of CRS and ICANS, as well as the availability of
socioeconomic support (ie, assessed willingness, understanding and ability to return to the medical center with
concerning signs and symptoms). Outpatient administration might be considered if a patient’s disease burden is
low. In this case, lower rates and delayed onset of CRS
are expected, allowing the patient to safely leave the infusion center while still vigilantly monitoring for symptoms
of CRS. Alternatively, if disease burden is high (tumor
bulk >10 cm and/or increased positron emission tomography (PET) metabolic tumor volume38) or is driving
active fevers and/or febrile neutropenia, assignment to
inpatient administration may be preferred because the
onset of CRS will likely be rapid and CRS may be severe,
requiring immediate intervention by the multidisciplinary team. Emerging factors associated with increased
incidence or greater severity of CRS and/or NE, include
elevated preinfusion lactate dehydrogenase, metabolic
tumor volume, Eastern Cooperative Oncology Group
performance status, and preinfusion C reactive protein
and ferritin levels.2 3 30 39–43 Although consideration of
these factors is important for predicting safety outcomes,
these factors are not 100% predictive.
Among patients with NHL, potentially complicating
patient-
related and disease-
related factors, including
secondary CNS disease, multiple comorbidities and age
(≥65 years), do not preclude treatment with CAR-T cell
therapy.10 44–47 For example, in a single-
center, retrospective analysis of 8 patients with active secondary CNS
lymphoma who received tisagenlecleucel therapy, no
patient experienced >1 event of grade 1 NE.45 Similarly,
findings from the US Lymphoma CAR-
T Consortium
demonstrated comparable rates of axicabtagene ciloleucel infusion, efficacy and safety outcomes in patients
with secondary CNS disease compared with patients
without CNS disease.44 As such, outpatient administration for these otherwise clinically challenging patients
should be considered because risk of complications is not
increased in these patient populations.
The patient’s level of social/familial support is another
key factor to consider. Outpatient administration
requires around-the-clock caregiver support during treatment and involves responsibility for a variety of tasks.48
For example, caregivers are commonly asked to keep a
written record of when medications are administered,
the patient’s body temperature, and the amount of fluids
consumed; understand the signs and symptoms of potential complications for which to seek immediate medical
Myers GD, et al. J Immunother Cancer 2021;9:e002056. doi:10.1136/jitc-2020-002056
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lisocabtagene maraleucel: TRANSCEND (9% treated as
outpatient), and two investigational ongoing trials for
treatment of r/r DLBCL with lisocabtagene maraleucel as
second-line therapy (41% treated as outpatient; PILOT,
NCT03483103) and third-
line or later therapy (65%
treated as outpatient; OUTREACH, NCT03744676).35
Patients were considered outpatients if they received lisocabtagene maraleucel infusion in the outpatient or inpatient setting and then left the clinic or were discharged
from the hospital on the day of infusion. Eighty-three per
cent of patients who received lisocabtagene maraleucel
in the outpatient setting did not require hospitalization
within the first 4 days after infusion, and 46% did not
require any hospitalization after infusion. Intensive care
unit (ICU)-level care was ultimately required in 3% of
patients who received outpatient infusions. The median
number of days of hospitalization following lisocabtagene
maraleucel infusion for inpatient infusion was 15 days
(range, 2–98 days; n=272) compared with 6 days (range,
2–23 days; n=18) for outpatients. Among patients in the
TRANSCEND trial who received lisocabtagene maraleucel
in the outpatient setting and then were admitted (n=18),
the median time to hospitalization was 5 days (range,
3–22 days), 6 patients (24%) were hospitalized on day 4
or earlier, and 1 patient (4%) required ICU admission.
Overall, patients who received lisocabtagene maraleucel
infusion in the outpatient setting required less hospitalization time compared with those who were infused in the
inpatient setting. This was likely driven by patient-specific
factors, such as disease burden. However, a reduction in
hospital admission days with outpatient CAR-T infusion
may be more convenient and preferred by patients and
health systems where this can be safely performed.
Tisagenlecleucel administration in the outpatient
setting has also been recently demonstrated in 30 patients
Hodgkin’s lymphoma (NHL) from a single-
with non-
center, retrospective study.36 Following outpatient infusion, 70% were managed entirely as outpatients. Of the
30% of patients admitted within the first 30 days after
infusion, most admissions were due to fever (89%; n=8)
resulting from CRS (63%; n=5) and infection (38%; n=3).
Outpatient administration is also being used in a
clinical trial of a third-generation CAR-T cell therapy.
MB-106, a fully humanized, third-
generation, CD20-
targeted CAR-T cell therapy that includes both the 4-1BB
and CD28 costimulatory domains, will be administered
in the outpatient setting in nearly all patients with NHL
in this single-center study.37 These observations suggest
that outpatient administration is becoming standard
practice as clinicians become familiar with safely infusing
CAR-T cell therapy in this setting; however, there exists
important patient-related considerations, aside from the
infusion procedure itself, that may be a barrier to outpatient administration (see next section).
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POSTINFUSION MONITORING AND PATIENT FOLLOW-UP
Patients who receive tisagenlecleucel are generally
instructed to remain within a 1-
hour transportation
distance from the outpatient center for at least 4 weeks
postinfusion for treatment of potential emergent procedural complications4; the Risk Evaluation and Mitigation
Strategy (REMS) for tisagenlecleucel indicates that patients
should plan to remain within 2 hours of the outpatient
center for at least 4 weeks. Similarly, patients who received
lisocabtagene maraleucel in TRANSCEND-
NHL-001
were instructed to remain within a 1-hour transportation
distance for 30 days.32 Patients considered ‘high risk’ due
to tumor bulk >10 cm, high lactate dehydrogenase or
multiple preexisting medical comorbidities, for example,
are commonly instructed to remain within a 30 min transportation distance; if possible, it is preferable for patients
to be housed in close proximity to the institution. Institutions may provide travel and lodging assistance through
support from insurance companies or CAR-T cell therapy
manufacturers for patients residing within a 30–60 min
transportation distance from the treatment center.50 The
outpatient approach is for patients to be monitored at the
Foundation for the Accreditation of Cellular Therapy-
accredited facility with 2–3 and sometimes daily visits
during the first week following infusion to monitor for
CRS and ICANS, in addition to laboratory monitoring for
tumor lysis syndrome or cytopenias. During the second
week, patients are monitored 2–4 times, then two times
per week for the following 2 weeks. With this approach,
outpatient administration of CAR-T cell therapy can be
successful, but critical to this effort is the awareness of
the variation in median time to CRS between CAR-T cell
therapies. Close contact is needed throughout the first
week with the CAR-T medical team, and rapid conversion to the 24-
hour monitored setting is required if
an observation or inpatient ward is needed for CRS or
Myers GD, et al. J Immunother Cancer 2021;9:e002056. doi:10.1136/jitc-2020-002056

other medical events. Outpatient administration should
be considered whenever feasible to reduce inpatient
healthcare utilization during the COVID-19 pandemic;
however, outpatient administration may not be practical
due to institutional resources and viral burden in the
surrounding community.51
Per industry and US Food and Drug Administration
(FDA) guidelines, including REMS, before receiving
treatment with FDA-
approved CAR-
T cell products
axicabtagene ciloleucel and tisagenlecleucel, patients
and caregivers must be provided with a patient wallet
card that advises on the signs and symptoms of CRS and
instructs when and how to contact the patient’s healthcare provider. The patient wallet card also includes directions for healthcare providers to consult the patient’s
treating oncologist if the patient requires steroids or cytotoxic medications, requires an invasive procedure, or has
a serious infection.
Considerations for hospital admission
The decision of when to admit patients following
outpatient CAR-
T cell infusion is a key consideration
and may vary across treatment centers. Typically, the
patient or caregiver contacts the treatment center to
report fever. The decision to admit the patient may vary
according to the patient’s predicted risk for progression to severe complications (eg, high baseline tumor
burden)40 42 52 53; however, patients with low disease
burden are often admitted. Based on the authors’ clinical experience, patients who receive tisagenlecleucel in
the outpatient setting are admitted for observation and/
or into the inpatient hospital ward if they develop a fever
(defined as ≥38°C) due to the potential for rapid progression of CRS and to evaluate for and treat infectious etiologies and sepsis. The majority of patients with fever are
admitted, particularly if fever occurs within 28 days postinfusion, if the patient is neutropenic, and/or if institutional logistical complications are evident. Occasionally,
with a single fever (<38°C and/or fever that dissipates
with hemodynamic stability), the decision to admit is
based on clinical course. The authors stress consideration
of typical complications of chemotherapy, such as bacteremia and sepsis, and thus recommend empiric antibiotic
use on admission for fever. Although infection prophylaxis is not required prior to infusion, local guidelines for
infection prophylaxis based on the degree of preceding
immunosuppression can be considered. When CAR-
T
cell therapy is administered in the outpatient setting, it is
also important for patients and caregivers to be educated
about the signs and symptoms of infections. If a patient
is readmitted for suspected infection, symptom-directed
broad-
spectrum antibiotics should be administered.54
For patients who receive tisagenlecleucel in the outpatient setting, CRS is diagnosed based on clinical signs and
symptoms, such as fever, hypoxia or hypotension.15–17
One unresolved issue is the criteria for hospital discharge
to the outpatient setting. Considerations include timing
of fever resolution from CAR-T cell infusion, presence/
5
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attention; provide transportation to and from hospital
visits; maintain cleanliness at home; manage the number
of in-home visitors to minimize the patient’s risk of exposure to anyone who is sick; communicate with and listen
to the patient; and understand the patient’s needs and
decisions.48 Thus, the potential for social/familial challenges associated with the caregiver’s ability to support
day-to-day medical needs, practical considerations and
emotional needs should be evaluated when considering
outpatient treatment.The outpatient social work service
performs a critical role by providing non-medical assessments to help guide the outpatient treatment decision.
On occasion, DLBCL patients are not treated with CAR-T
cell therapy following these assessments.49 For pediatric
patients with ALL who lack social/familial support, treatment with CAR-T cell therapy is typically administered in
the inpatient setting. Outpatient administration of CAR-T
cell therapy should be considered on a patient-by-patient
basis along with the practical and institutional conditions
presented herein.
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FINANCIAL IMPLICATIONS OF OUTPATIENT TREATMENT
Even though the cost of CAR-T cell therapies is high,
there is potential for reductions in these costs, and cost-
effectiveness profiles of CAR-T cell therapies should be
placed in the context of standard-of-care options. For
instance, administering CAR-T cell therapy to all indicated patients with r/r DLBCL would increase US healthcare costs by approximately US$10 billion over 5 years.55
Additionally, when tisagenlecleucel and axicabtagene
ciloleucel were each compared with salvage chemoimmunotherapy regimens and stem cell transplantation, both
therapies achieved a less than US$150 000 per quality-
adjusted life-years thresholds solitary, potentially curative
therapy with greatest benefit predicted for young patients
with ALL.55 56 In pediatric and young adult r/r B-ALL,
CAR-T cell therapy increased the total cost of treatment
by US$528 200 compared with standard-of-care chemotherapy, but increased effectiveness by 8.18 quality-
adjusted life-years.57 Currently, commercial CAR-T cell
therapy for r/r ALL is limited to patients ≤25 years of age.4
Early adult ALL studies were delayed due to perceived
toxicity and only now are reemerging as targets for future
clinical trials. Accordingly, allogeneic transplantation
offers the only opportunity for cure in these older ALL
patients, and there remains no meaningful therapy for
patients who relapse after transplantation or those who
6

have refractory disease. Thus, despite their costs, CAR-T
cell therapies have an acceptable cost-effectiveness profile
and, with ongoing improvements in manufacture, are
anticipated to further improve.
Variations in reimbursement policies in the USA based
on whether patients have public or private insurance
and whether they are infused in the inpatient or outpatient setting have significant implications for institutions,
payers and patients.58 For patients with private insurance,
often self-
funded plans supported by their employer,
preauthorization negotiations are the standard, whereby
drug reimbursement is frequently approved. However,
with governmental coverage (Centers for Medicare and
Medicaid Services; CMS), reimbursement is based on the
services provided based on a diagnostic code. Inpatient
reimbursement is based on a bundled charge, linked to
a diagnosis-related group (DRG) code, which is meant to
standardize prospective payments for an inpatient stay.
In the outpatient setting, reimbursement for services is
based on an ambulatory payment classification that bills
for daily services and is typically shared by the governmental payer and the patient copay. For CAR-
T cell
therapy in the outpatient setting, institutions are allowed
to bill Medicare the average sales price +6%,59 which leads
to full cost reimbursement for the CAR-T cell product.
CMS made a change to its policy early on that impacts
the copayment for patients receiving CAR-T cell therapy
in the outpatient setting in a positive way: the outpatient
drug copayment for patients receiving CAR-T cell therapy
is capped at the inpatient deductible amount of US$1408
(2020 rate).60 Normally, patients receiving drugs in the
outpatient setting have a 20% copayment.60 The financial responsibility of 20% of the current list price of the
commercially available CAR-
T cell therapies would be
unmanageable for nearly all patients.
The inpatient situation is different and currently is
under great scrutiny and significant evolution. Using
current CMS guidelines, the center receives a DRG code
bundled payment based on the rate associated with autologous stem cell transplantation (MS-DRG 016), which
is approximately 10-fold less than the cost of CAR-T cell
therapy. There have been some adjustments to make up
the difference, including the previous granting of new
technology add-on payments that cover up to 65% of the
cost of drug acquisition up to a maximum amount based
on total billed charges and the hospital’s overall cost-to-
charge ratio (CCR).61 However, as of September 30, 2020,
the NTAP was eliminated with the new CMS proposed
schedule61 and replaced by a new diagnostic code:
MS-DRG 018, CAR T-cell Immunotherapy. The proposed
unadjusted reimbursement rate of approximately US$239
400 appears to be a considerable improvement for
hospital systems over the previous rate of approximately
US$43 100 when inpatient CAR-T cell therapy services
were part of MS-DRG 016.62 In addition, outlier payments
may reimburse a significant percentage of the remaining
costs. Yet, inpatient coverage rates will still be predicted to
remain below hospitals’ costs.
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absence of documented infections and neutrophil status.
Counterbalancing the above with prolonged cytopenias
that are sometimes associated with CAR-T cell therapy
can be challenging. Additionally, myeloid growth factors,
such as granulocyte colony-stimulating factor (G-CSF),
traditionally have not been used early during the clinical testing of these products due to the theoretical risk
of exacerbating CRS. However, investigators have begun
to incorporate their use, with no clarity on start dates,
but generally no sooner than day 21–28 postinfusion. In
patients who experienced life-threatening infections, the
authors have safely used G-CSF as early as 2 weeks after
infusion. Care must be used to balance risks and benefits
of G-CSF during expanded commercial use of CAR-T cell
therapy in different clinical situations.
Coordination of multidisciplinary care is crucial for
treatment with CAR-T cell therapies in the outpatient
setting, particularly among on-
call oncology teams.
Clinical, emergency department and any other on-call
personnel at the treatment facility must be made aware
that the patient has received treatment with CAR-T cell
therapy, as they may be the point of first contact and their
center may manage complications. On-call services must
appropriately route patients and recognize that patients
who have received CAR-T cell therapy may have a lower
threshold for fever admission compared with other
oncology patients. Factors to consider before and after
outpatient administration are summarized in box 1.2 3
Additionally, recommendations for infection prevention
in these patients have recently been published.54

Open access

Factor category

Factor to be assessed

Specific considerations

Disease/clinical

Preinfusion LDH*

►► Subgroups defined for tisagenlecleucel: normal/low; high: 1–2×ULN, high: over 2×ULN†;

Metabolic tumor volume*

►► Patients considered high-risk due to tumor bulk >10 cm.§

Preinfusion CRP*

►► High CRP was associated with worse OS, but not PFS, in univariate Cox regression analysis.†
►► High CRP associated with CRS and NE, and is lower in patients with durable response.‡

Preinfusion ferritin*

►► High ferritin was associated with worse OS, but not PFS, in univariate Cox regression analyses.†
►► High CRP associated with CRS and NE, and is lower in patients with durable response.‡

ECOG PS*

►► ECOG PS 2–4 was associated with inferior outcomes.¶

Presence of secondary CNS
disease, multiple comorbidities
and age ≥65 years

►► Outpatient administration for these otherwise clinically challenging patients should be considered

Disease burden

►► Outpatient administration may not be suitable for patients with serious concurrent infection (eg,

subgroups as defined for lisocabtagene maraleucel: > or <500 U/L.‡

since risk of complications is not increased in these patient populations.**, ††, ‡‡, §§, ¶¶

invasive fungal disease) or presence of cytopenias with fever.

Patient

Capability of patients to return to ►► Willingness, understanding and ability to return to the medical center with concerning signs and
symptoms.
the hospital for fever
Socioeconomic support
Patient’s proximity to the treating
institution
Patient’s preference for
outpatient versus inpatient
infusion

►► Outpatient therapy allows a return to ‘normalcy’.

Reimbursement policies

►► Coverage variation between insurance types.

–– Private—reimbursement is frequently approved.
–– Public—reimbursement is based on the services provided, which vary between inpatient and
outpatient infusion.
►► Reimbursement implications need to be clarified/improved.
►► Variation concerning whether outpatient treatment will be beneficial to both patients and institution.
►► Rules for reimbursement are constantly evolving.
Institutional

Multidisciplinary team training

►► Proper institutional training and safeguards for the patient, physician (including on-call physicians),

Multidisciplinary team
communication plan

►► Communication with clinical, emergency department and any other on-call personnel at the

Reimbursement policies

►► Institutions are better positioned to avoid losses with outpatient infusion (overall cost-to-charge

the infusion center and emergency department personnel.

treatment facility.
–– May be the point of first contact to manage adverse events.
ratio, degree of price markups, option for outlier payments).

►► Reimbursement implications need to be clarified/improved.
►► Variation concerning whether outpatient treatment will be beneficial to both patients and institution.
Although consideration of these factors is important for predicting safety outcomes, these factors are not 100% predictive.
*Associations with elevated level/scores and increased incidence or greater severity of CRS and/or NE have beed reported.
†Westin et al.3
‡Siddiqi et al.42
§Nastoupil et al.2
¶Jacobson et al.39
**Pasquini et al.10
††Bennani et al.44
‡‡Frigault et al.45
§§Kilgore et al.46
¶¶Kittai et al.47
CAR-T, chimeric antigen receptor T-cell; CNS, central nervous system; CRP, C reactive protein; CRS, cytokine release syndrome; ECOG PS, Eastern Cooperative Oncology Group
performance status; LDH, lactate dehydrogenase; NE, neurological events; OS, overall survival; PFS, progression-free survival; ULN, upper limit of normal.

In order for hospitals to manage the financial impact
of offering CAR-T cell therapy, price markups should be
carefully considered. Payment is dependent on the total
billed charges for the case and the hospital’s CCR. The
unadjusted payment represents the payment amount
before the hospital’s CCR is applied by Medicare for
calculating the final payment. If the hospital charge for
the CAR-T cell product is set too low, the result will be
reimbursement from CMS that does not cover the full
hospital costs. If the charge is set too high, consumers
and industry watchdogs may raise concern, recognizing
that CAR-T cell therapy charges are publicly posted. In
addition, there are a small number of US cancer-focused
Myers GD, et al. J Immunother Cancer 2021;9:e002056. doi:10.1136/jitc-2020-002056

institutions that are exempt from the standard rules of
DRG reimbursement, and many CAR-
T cell therapy
patients have been treated in these institutions, thus
creating a blend of patient claims from which the estimated average reimbursement must be based. With all
these considerations, institutions are better positioned to
avoid cost losses with outpatient administration of CAR-T
cell therapy.
It is critical to be aware that if CAR-T cell therapy is
administered in the outpatient setting and a patient is
admitted within 3 days of infusion, Medicare applies all
charges incurred for the previous 72 hours to the inpatient
stay with its lower inpatient rate.58 Thus, reimbursement
7
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Table 1 Considerations for outpatient infusion of CAR-T cell therapy
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real-world data. Given the likely expansion of CAR-T cell
therapy technology and the desire to provide patients
with access to transformative therapies, reimbursement
guidelines should continuously be assessed.
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CONCLUSION
Outpatient administration of CAR-
T cell therapy can
be feasible and safe when institutions implement policies and procedures necessary for management of this
patient population. Additional findings from real-world
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procedures, particularly regarding defining needs and
quantifying subsequent hospital readmission following
infusion. For example, time from onset of symptoms to
hospital and/or ICU admission would be beneficial. Identification of reliable predictors, including biomarkers, of
severe treatment-associated complications, both general
and unique, as well as additional data from outpatient
CAR-T cell therapy in the real-world setting, will aid in
patient identification, risk reduction, and expanded
outpatient administration. Recommendations concerning
the potential cost savings with outpatient versus inpatient
administration of CAR-T cell therapy should be based on
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